Skip to main content

Table 2 The number of pXDDIs, for which the CP recommended drug discontinuation

From: Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation

pXDDIs

N prior

N after

pXDDIs

N prior

N after

 Amiodarone-torsemide

1

0

ipratropium / fenoterol-tiotropium

3

2

 Amiodarone-clozapine

1

0

quetiapine-amiodarone

1

0

 Amiodarone-warfarin

1

0

quetiapine -domperidone

2

1

 Etoricoxib-meloxicam

1

0

quetiapine -escitalopram

7

3

 Haloperidol-sulpiride

2

1

quetiapine-metoclopramide

3

2

 Haloperidol-metoclopramide

1

0

quetiapine-sulpiride

2

1

 Cholecalciferol-calcitriol

3

0

metoclopramide-trimetazidine

2

1

 Ipratropium/fenoterol-Olanzapine

2

1

sulpiride-risperidone

1

0

Not accepted pXDDIs

N prior

N after

pXDDIs

N prior

N after

 Amisulpride-sulpiride

1

1

quetiapine-budenoside / formoterol

1

1

 Desloratadine-mirtazapine

1

1

quetiapine-domperidone

2

1

 Escitalopram-sotalol

1

1

quetiapine-escitalopram

7

3

 Haloperidol-sulpiride

2

1

quetiapine-haloperidol

3

3

 Haloperidol- ipratropium/phenoterol

1

1

quetiapine-metoclopramide

3

2

 Haloperidol ipratropium/phenoterol-

1

1

quetiapine-sulpiride

2

1

 Olanzapine- ipratropium/phenoterol

2

1

quetiapine-trazodone

1

1

 Quetiapine-tiotropium

1

1

quetiapine-tiotropium

1

1

 Carbamazepine-clozapine

3

2

metoclopramide-trimetazidine

2

1

 Carvedilol- budenoside/formoterol

2

2

olanzapine-thyrotropium

1

1

 Quetiapine- ipratropium/phenoterol

1

1

sulpiride-trimetazidine

1

1